Evidence map›Paper›PMID 34108014›Full record

ArticleJournal of experimental & clinical cancer research : CR2021

Glycoproteomics identifies HOMER3 as a potentially targetable biomarker triggered by hypoxia and glucose deprivation in bladder cancer.

Andreia Peixoto, Dylan Ferreira, Rita Azevedo, Rui Freitas, Elisabete Fernandes, Marta Relvas-Santos, Cristiana Gaiteiro, Janine Soares, Sofia Cotton, Beatriz Teixeira and 8 more

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. TrimmedTheranostics · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

Andreia PeixotoExperimental Pathology and Therapeutics Group, Research Center (CI-IPOP), Portuguese Institute of Oncology, 4200-072, Porto, Portugal.
Dylan FerreiraExperimental Pathology and Therapeutics Group, Research Center (CI-IPOP), Portuguese Institute of Oncology, 4200-072, Porto, Portugal.
Rita AzevedoExperimental Pathology and Therapeutics Group, Research Center (CI-IPOP), Portuguese Institute of Oncology, 4200-072, Porto, Portugal.
Rui FreitasExperimental Pathology and Therapeutics Group, Research Center (CI-IPOP), Portuguese Institute of Oncology, 4200-072, Porto, Portugal.
Elisabete FernandesExperimental Pathology and Therapeutics Group, Research Center (CI-IPOP), Portuguese Institute of Oncology, 4200-072, Porto, Portugal.
Marta Relvas-SantosExperimental Pathology and Therapeutics Group, Research Center (CI-IPOP), Portuguese Institute of Oncology, 4200-072, Porto, Portugal.
Cristiana GaiteiroExperimental Pathology and Therapeutics Group, Research Center (CI-IPOP), Portuguese Institute of Oncology, 4200-072, Porto, Portugal.
Janine SoaresExperimental Pathology and Therapeutics Group, Research Center (CI-IPOP), Portuguese Institute of Oncology, 4200-072, Porto, Portugal.
Sofia CottonExperimental Pathology and Therapeutics Group, Research Center (CI-IPOP), Portuguese Institute of Oncology, 4200-072, Porto, Portugal.
Beatriz TeixeiraExperimental Pathology and Therapeutics Group, Research Center (CI-IPOP), Portuguese Institute of Oncology, 4200-072, Porto, Portugal.
Paula PauloCancer Genetics Group, Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), 4200-072, Porto, Portugal.
Luís LimaExperimental Pathology and Therapeutics Group, Research Center (CI-IPOP), Portuguese Institute of Oncology, 4200-072, Porto, Portugal.
Carlos PalmeiraExperimental Pathology and Therapeutics Group, Research Center (CI-IPOP), Portuguese Institute of Oncology, 4200-072, Porto, Portugal.
Gabriela MartinsImmunology Department, Portuguese Institute of Oncology of Porto, 4200-072, Porto, Portugal.
Maria José OliveiraInstitute for Research and Innovation in Health (i3S), University of Porto, 4200-135, Porto, Portugal.
André M N SilvaREQUIMTE-LAQV, Department of Chemistry and Biochemistry, Faculty of Sciences of the University of Porto, 4169-007, Porto, Portugal.
Lúcio Lara SantosExperimental Pathology and Therapeutics Group, Research Center (CI-IPOP), Portuguese Institute of Oncology, 4200-072, Porto, Portugal.
José Alexandre FerreiraExperimental Pathology and Therapeutics Group, Research Center (CI-IPOP), Portuguese Institute of Oncology, 4200-072, Porto, Portugal. jose.a.ferreira@ipoporto.min-saude.pt.ORCID http://orcid.org/0000-0002-0097-6148
Universidade do Porto · PTInstituto Português de Oncologia Francisco Gentil · PTFernando Pessoa University · PT

Funding

Fundação para a Ciência e a Tecnologia 2020.08708.BDFundação para a Ciência e a Tecnologia 2020.09384.BDFundação para a Ciência e a Tecnologia 2020.09394.BDFundação para a Ciência e a Tecnologia CEECIND/03186/2017Fundação para a Ciência e a Tecnologia SFRH/BD/103571/2014Fundação para a Ciência e a Tecnologia SFRH/BD/105355/2014Fundação para a Ciência e a Tecnologia SFRH/BD/111242/2015Fundação para a Ciência e a Tecnologia SFRH/BD/127327/2016Fundação para a Ciência e a Tecnologia SFRH/BD/142479/2018Fundação para a Ciência e a Tecnologia SFRH/BD/146500/2019
6 · The paper itself

Abstract

backgroundMuscle invasive bladder cancer (MIBC) remains amongst the deadliest genitourinary malignancies due to treatment failure and extensive molecular heterogeneity, delaying effective targeted therapeutics. Hypoxia and nutrient deprivation, oversialylation and O-glycans shortening are salient features of aggressive tumours, creating cell surface glycoproteome fingerprints with theranostics potential.

methodsA glycomics guided glycoproteomics workflow was employed to identify potentially targetable biomarkers using invasive bladder cancer cell models. The 5637 and T24 cells O-glycome was characterized by mass spectrometry (MS), and the obtained information was used to guide glycoproteomics experiments, combining sialidase, lectin affinity and bottom-up protein identification by nanoLC-ESI-MS/MS. Data was curated by a bioinformatics approach developed in-house, sorting clinically relevant molecular signatures based on Human Protein Atlas insights. Top-ranked targets and glycoforms were validated in cell models, bladder tumours and metastases by MS and immunoassays. Cells grown under hypoxia and glucose deprivation disclosed the contribution of tumour microenvironment to the expression of relevant biomarkers. Cancer-specificity was validated in healthy tissues by immunohistochemistry and MS in 20 types of tissues/cells of different individuals.

resultsSialylated T (ST) antigens were found to be the most abundant glycans in cell lines and over 900 glycoproteins were identified potentially carrying these glycans. HOMER3, typically a cytosolic protein, emerged as a top-ranked targetable glycoprotein at the cell surface carrying short-chain O-glycans. Plasma membrane HOMER3 was observed in more aggressive primary tumours and distant metastases, being an independent predictor of worst prognosis. This phenotype was triggered by nutrient deprivation and concomitant to increased cellular invasion. T24 HOMER3 knockdown significantly decreased proliferation and, to some extent, invasion in normoxia and hypoxia; whereas HOMER3 knock-in increased its membrane expression, which was more pronounced under glucose deprivation. HOMER3 overexpression was associated with increased cell proliferation in normoxia and potentiated invasion under hypoxia. Finally, the mapping of HOMER3-glycosites by EThcD-MS/MS in bladder tumours revealed potentially targetable domains not detected in healthy tissues.

conclusionHOMER3-glycoforms allow the identification of patients' subsets facing worst prognosis, holding potential to address more aggressive hypoxic cells with limited off-target effects. The molecular rationale for identifying novel bladder cancer molecular targets has been established.

Indexed as

BiomarkersCell HypoxiaCell ProliferationGlucoseGlycoproteinsHomer Scaffolding ProteinsHumansProteomicsTransfectionTumor MicroenvironmentUrinary Bladder NeoplasmsBiomarkersGlucoseGlycoproteinsHOMER3 protein, humanHomer Scaffolding ProteinsBladder cancerCancer microenvironmentGlycomicsGlycoproteomicsPrecision oncologyTargetable biomarkers

Identifiers

PMID34108014
PMCPMC8188679
OpenAlexW3170639749

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.